Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:mercury dibromide
go back to main search page
Accession:CHEBI:49639 term browser browse the term
Definition:A mercury coordination entity composed of mercury and bromine with the formula HgBr2.
Synonyms:exact_synonym: mercury(2+) bromide;   mercury(II) bromide
 related_synonym: DIBROMOMERCURY;   Formula=Br2Hg;   HgBr2;   InChI=1S/2BrH.Hg/h2*1H;/q;;+2/p-2;   InChIKey=NGYIMTKLQULBOO-UHFFFAOYSA-L;   SMILES=Br[Hg]Br;   mercuric bromide;   mercury bromide
 alt_id: CHEBI:33212;   CHEBI:49638
 xref: CAS:7789-47-1;   Gmelin:277818
 xref_mesh: MESH:C042720
 xref: PDBeChem:HG2;   PMID:15074688;   Reaxys:8127939;   Wikipedia:Mercury(II)_bromide


show annotations for term's descendants           Sort by:
mercury dibromide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A1bg alpha-1-B glycoprotein decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of A1BG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of A1BG mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:92,493,934...92,498,460
Ensembl chr 7:92,494,372...92,498,097 		JBrowse link
G Abcb6 ATP binding cassette subfamily B member 6 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ABCB6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCB6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ABCC4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCC4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ABCG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Abhd14a abhydrolase domain containing 14A decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ABHD14A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:107,079,139...107,089,004
Ensembl chr 8:107,079,144...107,086,985 		JBrowse link
G Abhd3 abhydrolase domain containing 3, phospholipase increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ABHD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABHD3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:1,723,203...1,778,488
Ensembl chr18:1,720,718...1,803,428 		JBrowse link
G Acp3 acid phosphatase 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA CTD PMID:27188386 NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236 		JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA CTD PMID:27188386 NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541 		JBrowse link
G Actg2 actin gamma 2, smooth muscle multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACTG2 mRNA CTD PMID:27188386 NCBI chr 4:116,021,832...116,046,475
Ensembl chr 4:116,021,832...116,046,465 		JBrowse link
G Actn3 actinin alpha 3 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ACTN3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACTN3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:202,159,081...202,175,012
Ensembl chr 1:202,159,082...202,175,012 		JBrowse link
G Adam28 ADAM metallopeptidase domain 28 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA CTD PMID:27188386 NCBI chr15:43,774,463...43,840,726
Ensembl chr15:42,944,467...43,840,672 		JBrowse link
G Adam9 ADAM metallopeptidase domain 9 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ADAM9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:67,022,538...67,101,647
Ensembl chr16:67,022,655...67,100,917 		JBrowse link
G Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ADAMTS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103 		JBrowse link
G Adamts12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ADAMTS12 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS12 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:60,032,873...60,327,629
Ensembl chr 2:60,032,873...60,327,629 		JBrowse link
G Adamts2 ADAM metallopeptidase with thrombospondin type 1 motif, 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS2 mRNA CTD PMID:27188386 NCBI chr10:34,920,992...35,126,465
Ensembl chr10:34,921,049...35,123,821 		JBrowse link
G Adamts20 ADAM metallopeptidase with thrombospondin type 1 motif, 20 decreases expression ISO mercuric bromide results in decreased expression of ADAMTS20 mRNA CTD PMID:26272509 NCBI chr 7:125,396,227...125,528,020
Ensembl chr 7:125,397,734...125,527,777 		JBrowse link
G Adcy2 adenylate cyclase 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ADCY2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCY2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:34,375,639...34,822,252
Ensembl chr 1:34,375,895...34,822,236 		JBrowse link
G Adcyap1r1 ADCYAP receptor type I decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ADCYAP1R1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADCYAP1R1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700 		JBrowse link
G Adgrg2 adhesion G protein-coupled receptor G2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ADGRG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:34,297,402...34,422,590
Ensembl chr  X:34,297,402...34,422,609 		JBrowse link
G Adgrg6 adhesion G protein-coupled receptor G6 multiple interactions
increases expression		 ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA
mercuric bromide results in increased expression of ADGRG6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:8,812,889...8,954,239
Ensembl chr 1:8,812,904...8,954,123 		JBrowse link
G Adm adrenomedullin multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADM mRNA CTD PMID:27188386 NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654 		JBrowse link
G Afap1l2 actin filament associated protein 1-like 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of AFAP1L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFAP1L2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:255,964,238...256,060,828
Ensembl chr 1:255,964,238...256,060,820 		JBrowse link
G Afp alpha-fetoprotein multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFP mRNA CTD PMID:27188386 NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480 		JBrowse link
G Agtr1a angiotensin II receptor, type 1a increases expression ISO mercuric bromide results in increased expression of AGTR1 mRNA CTD PMID:27188386 NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946 		JBrowse link
G Ajap1 adherens junctions associated protein 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of AJAP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:163,907,846...164,021,004
Ensembl chr 5:163,907,847...164,020,317 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of AKR1C1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of AKR1C2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of AKR1C3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873 		JBrowse link
G Alcam activated leukocyte cell adhesion molecule increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ALCAM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954 		JBrowse link
G Aldh1a3 aldehyde dehydrogenase 1 family, member A3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ALDH1A3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436 		JBrowse link
G Aldh1l2 aldehyde dehydrogenase 1 family, member L2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ALDH1L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:20,254,246...20,305,793
Ensembl chr 7:20,254,233...20,305,776 		JBrowse link
G Aldh3b2 aldehyde dehydrogenase 3 family, member B2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ALDH3B2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH3B2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:201,250,260...201,264,699
Ensembl chr 1:201,253,157...201,264,705
Ensembl chr 1:201,253,157...201,264,705 		JBrowse link
G Aldh3b3 aldehyde dehydrogenase 3 family, member B3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ALDH3B2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH3B2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:201,193,832...201,201,666
Ensembl chr 1:201,187,962...201,250,204 		JBrowse link
G Alkal2 ALK and LTK ligand 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ALKAL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:47,495,645...47,505,235
Ensembl chr 6:47,495,782...47,505,234 		JBrowse link
G Alpk2 alpha-kinase 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ALPK2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALPK2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:58,775,603...58,906,150
Ensembl chr18:58,775,605...58,906,258 		JBrowse link
G Ambp alpha-1-microglobulin/bikunin precursor increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of AMBP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMBP mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331 		JBrowse link
G Amer2 APC membrane recruitment protein 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of AMER2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:34,525,352...34,535,660
Ensembl chr15:34,524,542...34,528,455 		JBrowse link
G Amigo2 adhesion molecule with Ig like domain 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of AMIGO2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695 		JBrowse link
G Andpro androgen regulated protein multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CST4 mRNA CTD PMID:27188386 NCBI chr 3:136,718,601...136,725,131
Ensembl chr 3:136,718,602...136,724,966 		JBrowse link
G Ank1 ankyrin 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ANK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANK1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:68,876,294...69,054,963
Ensembl chr16:68,877,504...69,054,759 		JBrowse link
G Ankrd1 ankyrin repeat domain 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ANKRD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919 		JBrowse link
G Ankrd33b ankyrin repeat domain 33B increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ANKRD33B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD33B mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:82,277,604...82,359,420
Ensembl chr 2:82,283,108...82,358,872 		JBrowse link
G Antxr1 ANTXR cell adhesion molecule 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ANTXR1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANTXR1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:119,590,770...119,778,232
Ensembl chr 4:119,590,771...119,778,232 		JBrowse link
G Anxa1 annexin A1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ANXA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343 		JBrowse link
G Anxa2 annexin A2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ANXA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658 		JBrowse link
G Anxa3 annexin A3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ANXA3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617 		JBrowse link
G Anxa4 annexin A4 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ANXA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161 		JBrowse link
G Anxa9 annexin A9 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA CTD PMID:27188386 NCBI chr 2:182,873,185...182,884,501
Ensembl chr 2:182,872,929...182,883,374 		JBrowse link
G Aox1 aldehyde oxidase 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of AOX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770 		JBrowse link
G Apba2 amyloid beta precursor protein binding family A member 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of APBA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APBA2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:118,053,270...118,286,858
Ensembl chr 1:118,103,219...118,285,699 		JBrowse link
G Apcdd1 APC down-regulated 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of APCDD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APCDD1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:56,385,398...56,416,065
Ensembl chr18:56,385,264...56,416,070 		JBrowse link
G Apoa1 apolipoprotein A1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of APOA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOA1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035 		JBrowse link
G Apoa2 apolipoprotein A2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of APOA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of APOA2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355 		JBrowse link
G Arap2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ARAP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of ARAP2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:46,717,657...46,917,326
Ensembl chr14:46,718,760...46,917,154 		JBrowse link
G Arhgap18 Rho GTPase activating protein 18 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ARHGAP18 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:18,403,531...18,637,306
Ensembl chr 1:18,403,537...18,637,256 		JBrowse link
G Arhgdib Rho GDP dissociation inhibitor beta multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGDIB mRNA CTD PMID:27188386 NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658 		JBrowse link
G Arhgef25 Rho guanine nucleotide exchange factor 25 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ARHGEF25 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF25 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:63,005,938...63,013,325
Ensembl chr 7:63,005,940...63,013,719 		JBrowse link
G Arhgef9 Cdc42 guanine nucleotide exchange factor 9 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ARHGEF9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:59,919,560...60,077,538
Ensembl chr  X:59,920,870...60,077,513 		JBrowse link
G Arid5b AT-rich interaction domain 5B increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ARID5B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:20,307,731...20,490,746
Ensembl chr20:20,307,731...20,487,433 		JBrowse link
G Arl9 ARF like GTPase 9 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ARL9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:31,157,573...31,166,803
Ensembl chr14:31,157,586...31,166,699 		JBrowse link
G Arrb1 arrestin, beta 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ARRB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061 		JBrowse link
G Arrdc2 arrestin domain containing 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ARRDC2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARRDC2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:18,601,897...18,606,029
Ensembl chr16:18,601,897...18,606,029 		JBrowse link
G Arx aristaless related homeobox decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ARX mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:58,016,233...58,028,149
Ensembl chr  X:58,016,233...58,028,142 		JBrowse link
G Ascc3 activating signal cointegrator 1 complex subunit 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ASCC3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCC3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:53,510,137...53,795,446
Ensembl chr20:53,510,184...53,790,165 		JBrowse link
G Asf1a anti-silencing function 1A histone chaperone increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ASF1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASF1A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:32,893,962...32,908,808
Ensembl chr20:32,893,573...32,908,808 		JBrowse link
G Asic1 acid sensing ion channel subunit 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ASIC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:130,798,317...130,828,535
Ensembl chr 7:130,799,917...130,828,541 		JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ASNS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423 		JBrowse link
G Asphd1 aspartate beta-hydroxylase domain containing 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ASPHD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASPHD1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:181,552,968...181,556,902
Ensembl chr 1:181,552,884...181,556,090 		JBrowse link
G Astn1 astrotactin 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ASTN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:70,537,423...70,855,440
Ensembl chr13:70,537,703...70,855,440 		JBrowse link
G Atf3 activating transcription factor 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATF3 mRNA CTD PMID:27188386 NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631 		JBrowse link
G Atl3 atlastin GTPase 3 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ATL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATL3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:204,680,958...204,727,360
Ensembl chr 1:204,680,968...204,723,354 		JBrowse link
G Atp10d ATPase phospholipid transporting 10D (putative) increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ATP10D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP10D mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:35,911,728...36,012,549
Ensembl chr14:35,912,141...36,012,564 		JBrowse link
G Atp6v1c1 ATPase H+ transporting V1 subunit C1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ATP6V1C1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V1C1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:69,834,464...69,872,278
Ensembl chr 7:69,834,463...69,872,278 		JBrowse link
G Atp8a1 ATPase phospholipid transporting 8A1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ATP8A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP8A1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:40,315,013...40,557,572
Ensembl chr14:40,315,049...40,554,611 		JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ATP8B1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396 		JBrowse link
G B9d1 B9 domain containing 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of B9D1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B9D1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:46,186,222...46,196,309
Ensembl chr10:46,186,691...46,196,008 		JBrowse link
G Bag2 BAG cochaperone 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of BAG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:35,970,033...35,980,677
Ensembl chr 9:35,970,033...35,980,721 		JBrowse link
G Bag3 BAG cochaperone 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of BAG3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858 		JBrowse link
G Bambi BMP and activin membrane-bound inhibitor increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of BAMBI mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060 		JBrowse link
G Bbs9 Bardet-Biedl syndrome 9 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of BBS9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBS9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:21,013,865...21,437,934
Ensembl chr 8:21,013,944...21,437,930 		JBrowse link
G Bche butyrylcholinesterase decreases expression ISO mercuric bromide results in decreased expression of BCHE mRNA CTD PMID:26272509 NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148 		JBrowse link
G Bcl11a BCL11 transcription factor A increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of BCL11A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:98,029,018...98,124,181
Ensembl chr14:98,030,461...98,124,180 		JBrowse link
G Bcl2l11 Bcl2-like 11 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of BCL2L11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068 		JBrowse link
G Bco1 beta-carotene oxygenase 1 multiple interactions
decreases expression		 ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCO1 mRNA
mercuric bromide results in decreased expression of BCO1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:45,149,250...45,186,102
Ensembl chr19:45,149,265...45,186,101 		JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BDNF mRNA CTD PMID:27188386 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615 		JBrowse link
G Bend4 BEN domain containing 4 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of BEND4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:40,753,048...40,788,686
Ensembl chr14:40,753,077...40,783,504 		JBrowse link
G Bend6 BEN domain containing 6 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of BEND6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEND6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:36,081,033...36,135,309
Ensembl chr 9:36,081,484...36,135,228 		JBrowse link
G Best4 bestrophin 4 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of BEST4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:130,622,194...130,629,045
Ensembl chr 5:130,623,438...130,627,099 		JBrowse link
G Bhlhe40 basic helix-loop-helix family, member e40 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of BHLHE40 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774 		JBrowse link
G Bmp4 bone morphogenetic protein 4 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of BMP4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306 		JBrowse link
G Bmp5 bone morphogenetic protein 5 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of BMP5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925 		JBrowse link
G Bmp6 bone morphogenetic protein 6 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of BMP6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365 		JBrowse link
G Bmp7 bone morphogenetic protein 7 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of BMP7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788 		JBrowse link
G Bnc1 basonuclin zinc finger protein 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of BNC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:135,917,676...135,943,333
Ensembl chr 1:135,917,687...135,943,333 		JBrowse link
G Bnipl BCL2 interacting protein like multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA CTD PMID:27188386 NCBI chr 2:182,818,593...182,830,421
Ensembl chr 2:182,818,595...182,828,588 		JBrowse link
G Boc BOC cell adhesion associated, oncogene regulated decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of BOC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BOC mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:56,122,697...56,198,060
Ensembl chr11:56,122,750...56,198,059 		JBrowse link
G Bspry B-box and SPRY domain containing multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA CTD PMID:27188386 NCBI chr 5:75,927,397...75,949,585
Ensembl chr 5:75,927,405...75,949,583 		JBrowse link
G Bst2 bone marrow stromal cell antigen 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of BST2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BST2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979 		JBrowse link
G Btg2 BTG anti-proliferation factor 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of BTG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BTG2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628 		JBrowse link
G Btg3 BTG anti-proliferation factor 3 increases expression ISO mercuric bromide results in increased expression of BTG3 mRNA CTD PMID:26272509 NCBI chr11:17,030,156...17,046,069
Ensembl chr11:17,030,160...17,046,170 		JBrowse link
G C11h3orf70 similar to human chromosome 3 open reading frame 70 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of C3ORF70 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF70 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:79,345,857...79,396,140
Ensembl chr11:79,345,304...79,396,142 		JBrowse link
G C13h1orf226 similar to human chromosome 1 open reading frame 226 multiple interactions
decreases expression		 ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF226 mRNA
mercuric bromide results in decreased expression of C1ORF226 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:82,530,589...82,538,676
Ensembl chr13:82,530,577...82,820,949 		JBrowse link
G C14h4orf19 similar to human chromosome 4 open reading frame 19 increases expression ISO mercuric bromide results in increased expression of C4ORF19 mRNA CTD PMID:26272509 NCBI chr14:44,387,386...44,478,344
Ensembl chr14:44,387,393...44,478,041 		JBrowse link
G C1s complement C1s increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of C1S mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1S mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:157,430,249...157,442,438
Ensembl chr 4:157,430,117...157,442,303 		JBrowse link
G C3h11orf96 similar to human chromosome 11 open reading frame 96 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of C11ORF96 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C11ORF96 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:79,920,125...79,921,368
Ensembl chr 3:79,920,129...79,921,523 		JBrowse link
G C4h2orf68 similar to human chromosome 2 open reading frame 68 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of C2ORF68 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:104,402,553...104,408,317
Ensembl chr 4:104,402,588...104,408,320 		JBrowse link
G C5h1orf210 similar to human chromosome 1 open reading frame 210 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of C1ORF210 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1ORF210 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:132,048,755...132,051,913
Ensembl chr 5:132,048,773...132,051,925 		JBrowse link
G C8h11orf52 similar to human chromosome 11 open reading frame 52 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA CTD PMID:27188386 NCBI chr 8:51,081,342...51,088,333
Ensembl chr 8:51,081,342...51,094,533 		JBrowse link
G C9h6orf141 similar to human chromosome 6 open reading frame 141 decreases expression ISO mercuric bromide results in decreased expression of C6ORF141 mRNA CTD PMID:26272509 NCBI chr 9:20,024,916...20,029,094
Ensembl chr 9:20,024,916...20,029,094 		JBrowse link
G Cab39l calcium binding protein 39-like increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CAB39L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAB39L mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:33,606,588...33,710,518
Ensembl chr15:33,606,694...33,743,545 		JBrowse link
G Cachd1 cache domain containing 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CACHD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACHD1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:115,411,833...115,637,312
Ensembl chr 5:115,411,071...115,657,505 		JBrowse link
G Cacnb2 calcium voltage-gated channel auxiliary subunit beta 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA CTD PMID:27188386 NCBI chr17:77,564,630...77,910,000
Ensembl chr17:77,564,460...77,909,106 		JBrowse link
G Cadm2 cell adhesion molecule 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CADM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:4,548,367...5,525,420
Ensembl chr11:4,555,159...5,525,400 		JBrowse link
G Calb1 calbindin 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CALB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431 		JBrowse link
G Camk2d calcium/calmodulin-dependent protein kinase II delta increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CAMK2D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAMK2D mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178 		JBrowse link
G Camk2n1 calcium/calmodulin-dependent protein kinase II inhibitor 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CAMK2N1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK2N1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:150,674,819...150,676,600
Ensembl chr 5:150,673,507...150,676,600 		JBrowse link
G Car13 carbonic anhydrase 13 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA CTD PMID:27188386 NCBI chr 2:86,928,401...86,959,525
Ensembl chr 2:86,928,383...86,959,525 		JBrowse link
G Car4 carbonic anhydrase 4 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:69,827,945...69,836,501
Ensembl chr10:69,827,945...69,836,501 		JBrowse link
G Cars1 cysteinyl-tRNA synthetase 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CARS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CARS1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941 		JBrowse link
G Casp3 caspase 3 decreases activity ISO mercuric bromide results in decreased activity of CASP3 protein CTD PMID:26272509 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp8 caspase 8 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CASP8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Cav1 caveolin 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CAV1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705 		JBrowse link
G Cav2 caveolin 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CAV2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAV2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244 		JBrowse link
G Cc2d1b coiled-coil and C2 domain containing 1B increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CC2D1B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CC2D1B mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:123,353,289...123,367,343
Ensembl chr 5:123,353,292...123,367,318 		JBrowse link
G Ccar2 cell cycle and apoptosis regulator 2 decreases expression ISO mercuric bromide results in decreased expression of CCAR2 mRNA CTD PMID:26272509 NCBI chr15:45,212,797...45,228,001
Ensembl chr15:45,212,803...45,227,636 		JBrowse link
G Ccbe1 collagen and calcium binding EGF domains 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CCBE1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCBE1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:59,579,851...59,823,977
Ensembl chr18:59,580,768...59,824,400 		JBrowse link
G Ccdc102a coiled-coil domain containing 102A decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CCDC102A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC102A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:10,102,543...10,118,657
Ensembl chr19:10,103,361...10,118,657 		JBrowse link
G Ccdc113 coiled-coil domain containing 113 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CFAP263 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP263 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:9,497,000...9,516,917
Ensembl chr19:9,496,886...9,516,923 		JBrowse link
G Ccdc136 coiled-coil domain containing 136 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CCDC136 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:57,997,825...58,027,598
Ensembl chr 4:57,997,853...58,027,646 		JBrowse link
G Ccdc177 coiled-coil domain containing 177 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CCDC177 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:100,404,526...100,411,112
Ensembl chr 6:100,404,413...100,412,850 		JBrowse link
G Cckbr cholecystokinin B receptor decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CCKBR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881 		JBrowse link
G Ccn1 cellular communication network factor 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CCN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484 		JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN2 mRNA CTD PMID:27188386 NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734 		JBrowse link
G Ccng2 cyclin G2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CCNG2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830 		JBrowse link
G Cd40 CD40 molecule decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CD40 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CD40 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534 		JBrowse link
G Cd44 CD44 molecule multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA CTD PMID:27188386 NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620 		JBrowse link
G Cd82 Cd82 molecule decreases expression ISO mercuric bromide results in decreased expression of CD82 mRNA CTD PMID:26272509 NCBI chr 3:79,387,361...79,431,847
Ensembl chr 3:79,385,887...79,431,809 		JBrowse link
G Cd9 CD9 molecule increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CD9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222 		JBrowse link
G Cdc14b cell division cycle 14B multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC14B mRNA CTD PMID:27188386 NCBI chr17:844,686...934,787
Ensembl chr17:844,685...933,235 		JBrowse link
G Cdh1 cadherin 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CDH1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775 		JBrowse link
G Cdh10 cadherin 10 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CDH10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:68,628,623...68,850,995
Ensembl chr 2:68,628,780...68,850,995 		JBrowse link
G Cdh13 cadherin 13 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CDH13 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH13 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459 		JBrowse link
G Cdh3 cadherin 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CDH3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084 		JBrowse link
G Cdh6 cadherin 6 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CDH6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:62,079,139...62,225,298
Ensembl chr 2:62,079,137...62,225,228 		JBrowse link
G Cdh7 cadherin 7 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CDH7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:26,672,058...26,821,571
Ensembl chr13:26,672,484...26,819,846 		JBrowse link
G Cdh9 cadherin 9 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CDH9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:66,280,422...66,367,121
Ensembl chr 2:66,228,117...66,367,121 		JBrowse link
G Cdk19 cyclin-dependent kinase 19 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CDK19 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:43,770,409...43,910,629
Ensembl chr20:43,770,409...43,910,628 		JBrowse link
G Cdk6 cyclin-dependent kinase 6 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CDK6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CDKN1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN1A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CDKN2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN2A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149 		JBrowse link
G Cds1 CDP-diacylglycerol synthase 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CDS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDS1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CEBPB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473 		JBrowse link
G Cebpd CCAAT/enhancer binding protein delta multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA CTD PMID:27188386 NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829 		JBrowse link
G Celf5 CUGBP, Elav-like family member 5 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CELF5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:8,225,787...8,250,322
Ensembl chr 7:8,225,825...8,250,322 		JBrowse link
G Cep85l centrosomal protein 85-like increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CEP85L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:32,568,417...32,739,449
Ensembl chr20:32,572,741...32,739,516 		JBrowse link
G Cfap300 cilia and flagella associated protein 300 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CFAP300 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP300 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:5,180,180...5,198,840
Ensembl chr 8:5,180,675...5,198,807 		JBrowse link
G Cfap91 cilia and flagella associated protein 91 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CFAP91 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:62,413,613...62,457,281
Ensembl chr11:62,413,602...62,457,293 		JBrowse link
G Cfap96 cilia and flagella associated protein 96 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CFAP96 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP96 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:46,291,075...46,315,616
Ensembl chr16:46,291,311...46,315,625 		JBrowse link
G Cftr CF transmembrane conductance regulator increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CFTR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFTR mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756 		JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHAC1 mRNA CTD PMID:27188386 NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526 		JBrowse link
G Chka choline kinase alpha increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CHKA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHKA mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:201,076,804...201,125,517
Ensembl chr 1:201,076,860...201,125,516 		JBrowse link
G Chmp4c charged multivesicular body protein 4C increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CHMP4C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHMP4C mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:91,391,729...91,428,652
Ensembl chr 2:91,388,530...91,428,668 		JBrowse link
G Chodl chondrolectin increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CHODL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:17,654,137...17,676,450
Ensembl chr11:17,654,206...17,676,441 		JBrowse link
G Chordc1 cysteine and histidine rich domain containing 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHORDC1 mRNA CTD PMID:27188386 NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162 		JBrowse link
G Chrdl1 chordin-like 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CHRDL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRDL1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:106,889,125...106,992,937
Ensembl chr  X:106,889,125...106,992,921 		JBrowse link
G Cimap1b ciliary microtubule associated protein 1B decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CIMAP1B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CIMAP1B mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:120,444,232...120,447,294
Ensembl chr 7:120,444,232...120,446,749 		JBrowse link
G Cimap3 ciliary microtubule associated protein 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CIMAP3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:193,475,785...193,493,092
Ensembl chr 2:193,475,782...193,493,139 		JBrowse link
G Cldn11 claudin 11 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CLDN11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN11 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050 		JBrowse link
G Cldn18 claudin 18 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN18 mRNA CTD PMID:27188386 NCBI chr 8:100,246,499...100,265,797
Ensembl chr 8:100,247,633...100,273,351 		JBrowse link
G Cldn4 claudin 4 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CLDN4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436 		JBrowse link
G Cldn7 claudin 7 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CLDN7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171 		JBrowse link
G Clec18a C-type lectin domain family 18, member A decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CLEC18A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLEC18A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:39,038,498...39,053,425
Ensembl chr19:39,038,273...39,056,017 		JBrowse link
G Cln8 CLN8, transmembrane ER and ERGIC protein increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CLN8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLN8 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:74,749,662...74,759,553
Ensembl chr16:74,749,662...74,759,774 		JBrowse link
G Cnfn cornifelin decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CNFN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNFN mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:80,949,699...80,953,747
Ensembl chr 1:80,951,600...80,953,747 		JBrowse link
G Cnksr2 connector enhancer of kinase suppressor of Ras 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CNKSR2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:36,908,135...37,148,337
Ensembl chr  X:36,907,850...37,150,555 		JBrowse link
G Cnot4 CCR4-NOT transcription complex, subunit 4 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CNOT4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:63,712,770...63,814,355
Ensembl chr 4:63,712,770...63,814,360 		JBrowse link
G Cntn2 contactin 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CNTN2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:43,942,868...43,975,973
Ensembl chr13:43,947,265...43,975,887 		JBrowse link
G Cntnap3 contactin associated protein family member 3 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CNTNAP3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:267,379...455,478
Ensembl chr17:267,508...454,102 		JBrowse link
G Col11a1 collagen type XI alpha 1 chain increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of COL11A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL11A1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853 		JBrowse link
G Col12a1 collagen type XII alpha 1 chain increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of COL12A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL12A1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:80,547,592...80,665,665
Ensembl chr 8:80,547,593...80,665,686 		JBrowse link
G Col1a1 collagen type I alpha 1 chain increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of COL1A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Col1a2 collagen type I alpha 2 chain increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of COL1A2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867 		JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL3A1 mRNA CTD PMID:27188386 NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547 		JBrowse link
G Col6a3 collagen type VI alpha 3 chain multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA CTD PMID:27188386 NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471 		JBrowse link
G Col8a1 collagen type VIII alpha 1 chain multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL8A1 mRNA CTD PMID:27188386 NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424 		JBrowse link
G Colgalt2 collagen beta(1-O)galactosyltransferase 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of COLGALT2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:64,523,641...64,628,295
Ensembl chr13:64,523,658...64,627,549 		JBrowse link
G Cops8 COP9 signalosome subunit 8 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of COPS8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COPS8 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:91,207,427...91,217,258
Ensembl chr 9:91,207,395...91,217,258 		JBrowse link
G Cpe carboxypeptidase E increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CPE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233 		JBrowse link
G Cpeb2 cytoplasmic polyadenylation element binding protein 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CPEB2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPEB2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:67,787,503...67,839,973
Ensembl chr14:67,787,507...67,840,743 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CPT1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPT1A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055 		JBrowse link
G Cpxm2 carboxypeptidase X (M14 family), member 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CPXM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:186,836,797...186,947,222
Ensembl chr 1:186,836,797...186,947,220 		JBrowse link
G Creg1 cellular repressor of E1A-stimulated genes 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CREG1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CREG1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:78,019,814...78,032,310
Ensembl chr13:78,019,843...78,032,308 		JBrowse link
G Crim1 cysteine rich transmembrane BMP regulator 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CRIM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIM1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:16,695,864...16,870,264
Ensembl chr 6:16,697,829...16,870,259 		JBrowse link
G Cryba4 crystallin, beta A4 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CRYBA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:44,378,734...44,393,226
Ensembl chr12:44,378,737...44,393,221 		JBrowse link
G Csf2ra colony stimulating factor 2 receptor subunit alpha increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CSF2RA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:98,089...103,261
Ensembl chr14:89,172...103,128 		JBrowse link
G Cspg5 chondroitin sulfate proteoglycan 5 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CSPG5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:110,220,506...110,234,766
Ensembl chr 8:110,220,653...110,234,758 		JBrowse link
G Csrp1 cysteine and glycine-rich protein 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSRP1 mRNA CTD PMID:27188386 NCBI chr13:47,158,171...47,179,388
Ensembl chr13:47,167,789...47,179,384 		JBrowse link
G Ctdsp1 CTD small phosphatase 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CTDSP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTDSP1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:75,973,694...75,979,298
Ensembl chr 9:75,973,962...75,979,297 		JBrowse link
G Cth cystathionine gamma-lyase increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CTH mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTH mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234 		JBrowse link
G Cthrc1 collagen triple helix repeat containing 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CTHRC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:70,122,474...70,132,756
Ensembl chr 7:70,122,474...70,132,756 		JBrowse link
G Ctnnd2 catenin delta 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CTNND2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:81,168,525...82,016,495
Ensembl chr 2:81,167,117...82,015,764 		JBrowse link
G Cul3 cullin 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA CTD PMID:27188386 NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462 		JBrowse link
G Cxcl14 C-X-C motif chemokine ligand 14 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CXCL14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839 		JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of CXCR4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCR4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883 		JBrowse link
G Cyb5a cytochrome b5 type A increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CYB5A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYB5A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535
Ensembl chr18:78,202,342...78,258,535 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CYP1A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CYP1B1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917 		JBrowse link
G Cyth3 cytohesin 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of CYTH3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYTH3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:10,840,137...10,933,792
Ensembl chr12:10,840,157...10,933,812 		JBrowse link
G Dab1 DAB adaptor protein 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of DAB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552 		JBrowse link
G Dclk2 doublecortin-like kinase 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of DCLK2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:172,202,733...172,338,411
Ensembl chr 2:172,208,706...172,338,250 		JBrowse link
G Dcx doublecortin decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of DCX mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCX mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:107,430,767...107,573,612
Ensembl chr  X:107,430,767...107,507,476 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDIT3 mRNA CTD PMID:27188386 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Ddr2 discoidin domain receptor tyrosine kinase 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of DDR2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DDR2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363 		JBrowse link
G Dennd1b DENN domain containing 1B decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of DENND1B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:50,545,324...50,772,922
Ensembl chr13:50,545,836...50,770,601 		JBrowse link
G Dgki diacylglycerol kinase, iota decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of DGKI mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:65,410,878...65,872,733
Ensembl chr 4:65,420,108...65,872,733 		JBrowse link
G Dhrs11 dehydrogenase/reductase 11 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of DHRS11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHRS11 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295 		JBrowse link
G Dhx15 DEAH-box helicase 15 decreases expression ISO mercuric bromide results in decreased expression of DHX15 mRNA CTD PMID:26272509 NCBI chr14:58,787,147...58,825,083
Ensembl chr14:58,787,127...58,825,088 		JBrowse link
G Dipk1c divergent protein kinase domain 1C decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of DIPK1C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:78,087,972...78,109,910
Ensembl chr18:78,087,991...78,109,904 		JBrowse link
G Dlc1 DLC1 Rho GTPase activating protein increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of DLC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:55,246,716...55,671,441
Ensembl chr16:55,291,584...55,671,439 		JBrowse link
G Dll1 delta like canonical Notch ligand 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of DLL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:56,312,062...56,320,177
Ensembl chr 1:56,312,066...56,320,179 		JBrowse link
G Dlx3 distal-less homeobox 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of DLX3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:80,064,489...80,069,891
Ensembl chr10:80,064,489...80,069,872 		JBrowse link
G Dlx5 distal-less homeobox 5 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of DLX5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:34,999,139...35,003,504
Ensembl chr 4:34,999,139...35,003,407 		JBrowse link
G Dlx6 distal-less homeobox 6 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of DLX6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:34,984,264...34,989,926
Ensembl chr 4:34,984,232...34,991,343 		JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJB1 mRNA CTD PMID:27188386 NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458 		JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of DNAJC6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNAJC6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:116,120,069...116,283,448
Ensembl chr 5:116,119,676...116,283,448 		JBrowse link
G Dock6 dedicator of cytokinesis 6 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of DOCK6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:20,342,430...20,394,660
Ensembl chr 8:20,342,089...20,394,552 		JBrowse link
G Dock7 dedicator of cytokinesis 7 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of DOCK7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:113,599,371...113,782,871
Ensembl chr 5:113,600,198...113,782,813 		JBrowse link
G Dock8 dedicator of cytokinesis 8 decreases expression ISO mercuric bromide results in decreased expression of DOCK8 mRNA CTD PMID:26272509 NCBI chr 1:222,649,309...222,842,474
Ensembl chr 1:222,649,309...222,842,474 		JBrowse link
G Dock9 dedicator of cytokinesis 9 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of DOCK9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:98,611,518...98,883,306
Ensembl chr15:98,618,084...98,883,153 		JBrowse link
G Dqx1 DEAQ box RNA-dependent ATPase 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DQX1 mRNA CTD PMID:27188386 NCBI chr 4:115,563,497...115,572,598
Ensembl chr 4:115,563,752...115,572,590 		JBrowse link
G Drd4 dopamine receptor D4 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of DRD4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DRD4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553 		JBrowse link
G Dsc3 desmocollin 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of DSC3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:11,379,759...11,413,797
Ensembl chr18:11,377,347...11,413,797 		JBrowse link
G Dsp desmoplakin increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of DSP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSP mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:26,623,602...26,671,692
Ensembl chr17:26,623,588...26,671,800 		JBrowse link
G Dstyk dual serine/threonine and tyrosine protein kinase decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of DSTYK mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DSTYK mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:43,857,266...43,905,280
Ensembl chr13:43,857,266...43,905,269 		JBrowse link
G Dtna dystrobrevin, alpha increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of DTNA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DTNA mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:14,687,193...14,944,232
Ensembl chr18:14,587,852...14,944,261 		JBrowse link
G Dusp1 dual specificity phosphatase 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP1 mRNA CTD PMID:27188386 NCBI chr10:16,680,478...16,683,275 JBrowse link
G Dusp10 dual specificity phosphatase 10 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA CTD PMID:27188386 NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716 		JBrowse link
G Dusp14 dual specificity phosphatase 14 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of DUSP14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP14 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:68,936,483...68,966,347
Ensembl chr10:68,935,330...68,965,329 		JBrowse link
G Dusp2 dual specificity phosphatase 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP2 mRNA CTD PMID:27188386 NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499 		JBrowse link
G Dusp5 dual specificity phosphatase 5 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of DUSP5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818 		JBrowse link
G Dusp8 dual specificity phosphatase 8 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP8 mRNA CTD PMID:27188386 NCBI chr 1:197,167,392...197,184,285
Ensembl chr 1:197,169,422...197,182,921 		JBrowse link
G Eaf2 ELL associated factor 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of EAF2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610 		JBrowse link
G Ebf1 EBF transcription factor 1 decreases expression ISO mercuric bromide results in decreased expression of EBF1 mRNA CTD PMID:26272509 NCBI chr10:29,095,858...29,489,142
Ensembl chr10:29,099,933...29,487,665 		JBrowse link
G Edn1 endothelin 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA CTD PMID:27188386 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885 		JBrowse link
G Ednrb endothelin receptor type B increases expression ISO mercuric bromide results in increased expression of EDNRB mRNA CTD PMID:26272509 NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115 		JBrowse link
G Eef1akmt2 EEF1A lysine methyltransferase 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of EEF1AKMT2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EEF1AKMT2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:187,616,156...187,640,934
Ensembl chr 1:187,500,744...187,640,937 		JBrowse link
G Efhc2 EF-hand domain containing 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFHC2 mRNA CTD PMID:27188386 NCBI chr  X:5,360,499...5,564,004
Ensembl chr  X:5,360,617...5,560,970 		JBrowse link
G Efna1 ephrin A1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA CTD PMID:27188386 NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866 		JBrowse link
G Efna2 ephrin A2 decreases expression ISO mercuric bromide results in decreased expression of EFNA2 mRNA CTD PMID:26272509 NCBI chr 7:9,515,635...9,528,071
Ensembl chr 7:9,516,429...9,527,061 		JBrowse link
G Egf epidermal growth factor multiple interactions
increases expression		 ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGF mRNA
mercuric bromide results in increased expression of EGF mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064 		JBrowse link
G Egfl7 EGF-like-domain, multiple 7 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of EGFL7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFL7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:9,404,622...9,416,879
Ensembl chr 3:9,407,520...9,416,879 		JBrowse link
G Eid3 EP300 interacting inhibitor of differentiation 3 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of EID3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:20,860,073...20,861,395 JBrowse link
G Eif4e3 eukaryotic translation initiation factor 4E family member 3 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of EIF4E3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:132,258,502...132,301,808
Ensembl chr 4:132,258,502...132,301,808 		JBrowse link
G Elf3 E74 like ETS transcription factor 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA CTD PMID:27188386 NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481 		JBrowse link
G Elf4 E74 like ETS transcription factor 4 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ELF4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:127,587,401...127,639,063
Ensembl chr  X:127,590,650...127,630,200 		JBrowse link
G Elf5 E74 like ETS transcription factor 5 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ELF5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:89,808,837...89,836,977
Ensembl chr 3:89,797,880...89,836,973 		JBrowse link
G Elk3 ETS transcription factor ELK3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ELK3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:27,768,582...27,831,088
Ensembl chr 7:27,768,599...27,804,084 		JBrowse link
G Elmod1 ELMO domain containing 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ELMOD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:54,298,363...54,355,348
Ensembl chr 8:54,298,363...54,355,140 		JBrowse link
G Emp1 epithelial membrane protein 1 increases expression ISO mercuric bromide results in increased expression of EMP1 mRNA CTD PMID:26272509 NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904 		JBrowse link
G Ensa endosulfine alpha increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ENSA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENSA mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:183,185,552...183,192,888
Ensembl chr 2:183,185,552...183,194,847 		JBrowse link
G Eogt EGF domain specific O-linked N-acetylglucosamine transferase increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of EOGT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:129,718,897...129,756,558
Ensembl chr 4:129,718,901...129,756,445 		JBrowse link
G Epas1 endothelial PAS domain protein 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of EPAS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228 		JBrowse link
G Epb41l3 erythrocyte membrane protein band 4.1-like 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA CTD PMID:27188386 NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607 		JBrowse link
G Epb41l5 erythrocyte membrane protein band 4.1 like 5 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of EPB41L5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:30,670,792...30,770,213
Ensembl chr13:30,669,764...30,768,360 		JBrowse link
G Epcam epithelial cell adhesion molecule increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of EPCAM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127 		JBrowse link
G Epdr1 ependymin related 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of EPDR1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPDR1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:45,333,932...45,358,597
Ensembl chr17:45,333,956...45,358,594 		JBrowse link
G Epha2 Eph receptor A2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA2 mRNA CTD PMID:27188386 NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117 		JBrowse link
G Ephb1 Eph receptor B1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of EPHB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:102,507,549...102,944,839
Ensembl chr 8:102,507,549...102,944,839 		JBrowse link
G Ephb2 Eph receptor B2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of EPHB2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059 		JBrowse link
G Epn3 epsin 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of EPN3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:79,438,978...79,449,516
Ensembl chr10:79,438,978...79,447,356 		JBrowse link
G Eps8l2 EPS8-like 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of EPS8L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:196,446,260...196,471,544
Ensembl chr 1:196,446,287...196,471,541 		JBrowse link
G Epsti1 epithelial stromal interaction 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of EPSTI1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:53,283,964...53,382,192
Ensembl chr15:53,284,216...53,382,191 		JBrowse link
G Erap1 endoplasmic reticulum aminopeptidase 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ERAP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:3,931,817...3,970,735
Ensembl chr 2:3,931,904...3,972,447 		JBrowse link
G Erich1 glutamate-rich 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ERICH1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERICH1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:75,501,322...75,569,129
Ensembl chr16:75,501,384...75,569,128 		JBrowse link
G Erich5 glutamate-rich 5 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ERICH5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERICH5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:65,655,829...65,682,221
Ensembl chr 7:65,657,204...65,680,207 		JBrowse link
G Ero1b endoplasmic reticulum oxidoreductase 1 beta multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERO1B mRNA CTD PMID:27188386 NCBI chr17:85,861,086...86,003,244
Ensembl chr17:85,929,618...86,003,398 		JBrowse link
G Erp27 endoplasmic reticulum protein 27 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ERP27 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:169,804,656...169,821,660
Ensembl chr 4:169,804,658...169,821,660 		JBrowse link
G Esrp1 epithelial splicing regulatory protein 1 increases expression ISO mercuric bromide results in increased expression of ESRP1 mRNA CTD PMID:26272509 NCBI chr 5:24,427,611...24,482,157
Ensembl chr 5:24,428,717...24,482,062 		JBrowse link
G Esrp2 epithelial splicing regulatory protein 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ESRP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:34,034,559...34,041,726
Ensembl chr19:34,034,559...34,041,726 		JBrowse link
G Etl4 enhancer trap locus 4 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of KIAA1217 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1217 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:82,841,075...83,304,868
Ensembl chr17:82,495,041...83,304,715 		JBrowse link
G Etnk1 ethanolamine kinase 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ETNK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:176,126,056...176,170,325
Ensembl chr 4:176,126,180...176,193,770 		JBrowse link
G Ets1 ETS proto-oncogene 1, transcription factor increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ETS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010 		JBrowse link
G Evc2 EvC ciliary complex subunit 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EVC2 mRNA CTD PMID:27188386 NCBI chr14:73,366,832...73,454,539
Ensembl chr14:73,367,963...73,454,516 		JBrowse link
G F2rl2 coagulation factor II (thrombin) receptor-like 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of F2RL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:26,972,054...26,977,098
Ensembl chr 2:26,972,054...26,977,098 		JBrowse link
G F3 coagulation factor III, tissue factor increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of F3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668 		JBrowse link
G F5 coagulation factor V increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of F5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317 		JBrowse link
G Fam110c family with sequence similarity 110, member C increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FAM110C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110C mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:47,638,466...47,644,723
Ensembl chr 6:47,638,276...47,644,634 		JBrowse link
G Fam124a family with sequence similarity 124 member A decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of FAM124A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:36,799,836...36,855,062
Ensembl chr15:36,799,877...36,853,683 		JBrowse link
G Fam13c family with sequence similarity 13, member C increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FAM13C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:18,065,625...18,187,792
Ensembl chr20:18,065,628...18,187,592 		JBrowse link
G Fam149a family with sequence similarity 149, member A decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of FAM149A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:46,855,377...46,914,553
Ensembl chr16:46,854,635...46,912,066 		JBrowse link
G Fam169a family with sequence similarity 169, member A increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FAM169A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM169A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:28,384,162...28,441,361
Ensembl chr 2:28,383,784...28,438,910 		JBrowse link
G Fam222a family with sequence similarity 222, member A decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of FAM222A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:41,982,064...42,033,085
Ensembl chr12:41,986,780...42,033,682 		JBrowse link
G Fam241a family with sequence similarity 241 member A multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA CTD PMID:27188386 NCBI chr 2:216,344,563...216,375,193
Ensembl chr 2:216,343,822...216,375,242 		JBrowse link
G Fam89a family with sequence similarity 89, member A increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FAM89A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:52,710,002...52,722,630
Ensembl chr19:52,710,019...52,722,631 		JBrowse link
G Fas Fas cell surface death receptor increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FAS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAS mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591 		JBrowse link
G Fblim1 filamin binding LIM protein 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBLIM1 mRNA CTD PMID:27188386 NCBI chr 5:153,883,945...153,915,524
Ensembl chr 5:153,883,960...153,913,757 		JBrowse link
G Fbxo9 f-box protein 9 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of FBXO9 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:78,958,482...78,984,015
Ensembl chr 8:78,958,483...78,983,949 		JBrowse link
G Fech ferrochelatase increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FECH mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FECH mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348 		JBrowse link
G Fez1 fasciculation and elongation protein zeta 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of FEZ1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:36,544,462...36,589,684
Ensembl chr 8:36,544,535...36,589,683 		JBrowse link
G Fezf2 Fez family zinc finger 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of FEZF2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:12,768,614...12,777,554
Ensembl chr15:12,773,762...12,777,554 		JBrowse link
G Fgb fibrinogen beta chain increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FGB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGB mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979 		JBrowse link
G Fgf9 fibroblast growth factor 9 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA CTD PMID:27188386 NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309 		JBrowse link
G Fgfr2 fibroblast growth factor receptor 2 decreases expression ISO mercuric bromide results in decreased expression of FGFR2 mRNA CTD PMID:26272509 NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626 		JBrowse link
G Fhod3 formin homology 2 domain containing 3 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of FHOD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:15,993,079...16,425,796
Ensembl chr18:15,993,324...16,425,796 		JBrowse link
G Fjx1 four-jointed box kinase 1 decreases expression ISO mercuric bromide results in decreased expression of FJX1 mRNA CTD PMID:26272509 NCBI chr 3:88,774,220...88,776,321
Ensembl chr 3:88,774,220...88,776,321 		JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of FKBP5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FKBP5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674 		JBrowse link
G Fli1 Fli-1 proto-oncogene, ETS transcription factor multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLI1 mRNA CTD PMID:27188386 NCBI chr 8:30,831,422...30,950,468
Ensembl chr 8:30,832,753...30,950,433 		JBrowse link
G Flnb filamin B increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FLNB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLNB mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:16,961,999...17,095,059
Ensembl chr15:16,962,003...17,095,006 		JBrowse link
G Flnc filamin C increases expression ISO mercuric bromide results in increased expression of FLNC mRNA CTD PMID:26272509 NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844 		JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FLT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626 		JBrowse link
G Fn1 fibronectin 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FN1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678 		JBrowse link
G Fndc4 fibronectin type III domain containing 4 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of FNDC4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:25,077,155...25,080,812
Ensembl chr 6:25,077,349...25,080,675 		JBrowse link
G Fndc5 fibronectin type III domain containing 5 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of FNDC5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:141,481,593...141,491,257
Ensembl chr 5:141,481,590...141,490,731 		JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FOSL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930 		JBrowse link
G Fosl2 FOS like 2, AP-1 transcription factor subunit increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FOSL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOSL2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034 		JBrowse link
G Foxc1 forkhead box C1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FOXC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:32,631,379...32,635,361
Ensembl chr17:32,633,142...32,634,803 		JBrowse link
G Foxc2 forkhead box C2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA CTD PMID:27188386 NCBI chr19:49,186,034...49,188,736
Ensembl chr19:49,185,662...49,188,737 		JBrowse link
G Foxl2 forkhead box L2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FOXL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXL2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:99,512,971...99,514,500
Ensembl chr 8:99,513,303...99,514,427 		JBrowse link
G Frem1 Fras1 related extracellular matrix 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FREM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:97,321,266...97,469,523
Ensembl chr 5:97,322,538...97,469,543 		JBrowse link
G Frmd3 FERM domain containing 3 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of FRMD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:87,764,755...88,031,091
Ensembl chr 5:87,764,604...88,031,091 		JBrowse link
G Frzb frizzled-related protein multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA CTD PMID:27188386 NCBI chr 3:65,332,274...65,365,208
Ensembl chr 3:65,332,277...65,365,208 		JBrowse link
G Fth1 ferritin heavy chain 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FTH1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTH1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424 		JBrowse link
G Ftl1 ferritin light chain 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of FTL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTL mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725
Ensembl chr 2:95,936,387...95,939,725 		JBrowse link
G Ftx FTX transcript, XIST regulator increases expression ISO mercuric bromide results in increased expression of FTX mRNA CTD PMID:26272509 NCBI chr  X:68,588,349...68,630,338 JBrowse link
G Fzd10 frizzled class receptor 10 decreases expression ISO mercuric bromide results in decreased expression of FZD10 mRNA CTD PMID:26272509 NCBI chr12:28,098,371...28,101,566
Ensembl chr12:28,098,371...28,101,566 		JBrowse link
G Gabarapl1 GABA type A receptor associated protein like 1 increases expression ISO mercuric bromide results in increased expression of GABARAPL1 mRNA CTD PMID:26272509 NCBI chr 4:162,980,309...162,989,452
Ensembl chr 4:162,980,249...162,989,450 		JBrowse link
G Gabra5 gamma-aminobutyric acid type A receptor subunit alpha 5 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GABRA5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:108,268,728...108,381,670
Ensembl chr 1:108,268,776...108,380,917 		JBrowse link
G Gabrb2 gamma-aminobutyric acid type A receptor subunit beta 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GABRB2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251 		JBrowse link
G Gabrb3 gamma-aminobutyric acid type A receptor subunit beta 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GABRB3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961 		JBrowse link
G Gabrp gamma-aminobutyric acid type A receptor subunit pi increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GABRP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:18,143,031...18,169,595
Ensembl chr10:18,143,038...18,169,516 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GADD45A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115 		JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA CTD PMID:27188386 NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046 		JBrowse link
G Gal galanin and GMAP prepropeptide decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GAL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAL mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959 		JBrowse link
G Galnt10 polypeptide N-acetylgalactosaminyltransferase 10 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GALNT10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT10 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:41,821,216...41,967,618
Ensembl chr10:41,820,158...41,967,013 		JBrowse link
G Galnt14 polypeptide N-acetylgalactosaminyltransferase 14 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GALNT14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT14 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:21,756,039...21,977,533
Ensembl chr 6:21,755,195...21,972,192 		JBrowse link
G Galnt3 polypeptide N-acetylgalactosaminyltransferase 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GALNT3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:50,742,500...50,779,266
Ensembl chr 3:50,742,512...50,766,268 		JBrowse link
G Galp galanin-like peptide decreases expression ISO mercuric bromide results in decreased expression of GALP mRNA CTD PMID:26272509 NCBI chr 1:67,684,023...67,703,121
Ensembl chr 1:67,684,025...67,702,269 		JBrowse link
G Gas1 growth arrest-specific 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GAS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:4,482,168...4,485,153 JBrowse link
G Gas2l1 growth arrest-specific 2 like 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GAS2L1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS2L1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:79,955,350...79,961,830
Ensembl chr14:79,950,555...79,961,438 		JBrowse link
G Gask1b golgi associated kinase 1B multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GASK1B mRNA CTD PMID:27188386 NCBI chr 2:165,047,689...165,112,479
Ensembl chr 2:165,047,684...165,112,477 		JBrowse link
G Gata2 GATA binding protein 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GATA2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761 		JBrowse link
G Gata3 GATA binding protein 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GATA3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391 		JBrowse link
G Gata6 GATA binding protein 6 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GATA6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GCLC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLC mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GCLM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCLM mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Gcnt1 glucosaminyl (N-acetyl) transferase 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GCNT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GCNT1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:214,718,344...214,755,735
Ensembl chr 1:214,718,293...214,758,776 		JBrowse link
G Gdap1l1 ganglioside-induced differentiation-associated protein 1-like 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GDAP1L1 mRNA CTD PMID:27188386 NCBI chr 3:152,110,225...152,129,693
Ensembl chr 3:152,110,253...152,128,711 		JBrowse link
G Gdf15 growth differentiation factor 15 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GDF15 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF15 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055 		JBrowse link
G Gjb2 gap junction protein, beta 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA CTD PMID:27188386 NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177 		JBrowse link
G Glipr1 GLI pathogenesis-related 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLIPR1 mRNA CTD PMID:27188386 NCBI chr 7:47,487,342...47,498,974
Ensembl chr 7:47,487,345...47,498,429 		JBrowse link
G Glis3 GLIS family zinc finger 3 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GLIS3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:225,976,029...226,395,849
Ensembl chr 1:225,976,326...226,395,899 		JBrowse link
G Glrx2 glutaredoxin 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GLRX2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:55,481,875...55,504,737
Ensembl chr13:55,482,694...55,492,831 		JBrowse link
G Gls glutaminase increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GLS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900 		JBrowse link
G Gna14 G protein subunit alpha 14 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GNA14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNA14 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:213,716,020...213,897,423 		JBrowse link
G Gnas GNAS complex locus increases expression ISO mercuric bromide results in increased expression of GNAS mRNA CTD PMID:26272509 NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262 		JBrowse link
G Gne glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GNE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNE mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:58,267,189...58,307,396
Ensembl chr 5:58,267,210...58,307,499 		JBrowse link
G Gng11 G protein subunit gamma 11 increases expression ISO mercuric bromide results in increased expression of GNG11 mRNA CTD PMID:26272509 NCBI chr 4:32,023,003...32,028,443
Ensembl chr 4:32,023,003...32,028,442 		JBrowse link
G Gng8 G protein subunit gamma 8 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GNG8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:77,564,512...77,568,371
Ensembl chr 1:77,564,515...77,568,371 		JBrowse link
G Gpat3 glycerol-3-phosphate acyltransferase 3 multiple interactions
increases expression		 ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPAT3 mRNA
mercuric bromide results in increased expression of GPAT3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:8,715,367...8,768,051
Ensembl chr14:8,714,373...8,766,490 		JBrowse link
G Gpm6a glycoprotein m6a increases expression ISO mercuric bromide results in increased expression of GPM6A mRNA CTD PMID:26272509 NCBI chr16:36,641,282...36,973,377
Ensembl chr16:36,641,284...36,973,475 		JBrowse link
G Gpm6b glycoprotein m6b decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GPM6B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPM6B mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:28,057,788...28,204,409
Ensembl chr  X:28,059,450...28,204,211 		JBrowse link
G Gpnmb glycoprotein nmb increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GPNMB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPNMB mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367 		JBrowse link
G Gpr153 G protein-coupled receptor 153 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GPR153 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR153 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:162,781,587...162,792,975
Ensembl chr 5:162,781,587...162,792,971 		JBrowse link
G Gpr27 G protein-coupled receptor 27 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GPR27 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:132,328,364...132,329,497
Ensembl chr 4:132,328,364...132,329,497 		JBrowse link
G Gpr37 G protein-coupled receptor 37 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GPR37 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:54,138,860...54,160,927
Ensembl chr 4:54,138,870...54,161,001 		JBrowse link
G Gpr39 G protein-coupled receptor 39 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GPR39 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR39 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:37,115,258...37,327,312
Ensembl chr13:37,115,102...37,328,267 		JBrowse link
G Gpr87 G protein-coupled receptor 87 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GPR87 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR87 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:143,439,741...143,440,901
Ensembl chr 2:143,439,735...143,458,190 		JBrowse link
G Gprc5a G protein-coupled receptor, class C, group 5, member A increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GPRC5A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPRC5A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:167,903,542...167,922,276
Ensembl chr 4:167,903,542...167,922,260 		JBrowse link
G Gpx3 glutathione peroxidase 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPX3 mRNA CTD PMID:27188386 NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035 		JBrowse link
G Gramd1c GRAM domain containing 1C decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GRAMD1C mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRAMD1C mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:56,633,229...56,718,570
Ensembl chr11:56,633,227...56,718,570 		JBrowse link
G Grem1 gremlin 1, DAN family BMP antagonist increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GREM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082 		JBrowse link
G Grhl1 grainyhead-like transcription factor 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA CTD PMID:27188386 NCBI chr 6:41,207,325...41,257,516
Ensembl chr 6:41,207,348...41,254,301 		JBrowse link
G Grhl2 grainyhead-like transcription factor 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GRHL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:68,400,287...68,530,269
Ensembl chr 7:68,400,477...68,530,258 		JBrowse link
G Grhl3 grainyhead-like transcription factor 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GRHL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:147,774,161...147,806,291
Ensembl chr 5:147,774,160...147,806,160 		JBrowse link
G Gria3 glutamate ionotropic receptor AMPA type subunit 3 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GRIA3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:120,238,515...120,504,106
Ensembl chr  X:120,238,534...120,504,096 		JBrowse link
G Grin2a glutamate ionotropic receptor NMDA type subunit 2A decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GRIN2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637 		JBrowse link
G Gsr glutathione-disulfide reductase increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GSR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSR mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661 		JBrowse link
G Gstm2 glutathione S-transferase mu 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of GSTM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSTM2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961 		JBrowse link
G Gstp1 glutathione S-transferase pi 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GSTP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GSTP1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226 		JBrowse link
G Guca1a guanylate cyclase activator 1A multiple interactions
decreases expression		 ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUCA1A mRNA
mercuric bromide results in decreased expression of GUCA1A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:13,588,988...13,598,566
Ensembl chr 9:13,588,525...13,598,565 		JBrowse link
G Gulp1 GULP PTB domain containing engulfment adaptor 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of GULP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GULP1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:46,622,699...46,899,005
Ensembl chr 9:46,622,669...46,899,005 		JBrowse link
G Gxylt2 glucoside xylosyltransferase 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GXYLT2 mRNA CTD PMID:27188386 NCBI chr 4:133,347,230...133,449,708
Ensembl chr 4:133,347,499...133,449,454 		JBrowse link
G H4f3 H1.3 linker histone, cluster member decreases expression ISO mercuric bromide results in decreased expression of H1-3 mRNA CTD PMID:26272509 NCBI chr17:41,551,524...41,552,303
Ensembl chr17:41,529,667...41,552,334 		JBrowse link
G Hacd1 3-hydroxyacyl-CoA dehydratase 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of HACD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:77,081,508...77,106,114
Ensembl chr17:77,083,740...77,106,073 		JBrowse link
G Hand1 heart and neural crest derivatives expressed 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA CTD PMID:27188386 NCBI chr10:42,006,646...42,009,213
Ensembl chr10:42,006,651...42,009,213 		JBrowse link
G Hapln1 hyaluronan and proteoglycan link protein 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of HAPLN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777 		JBrowse link
G Hdlbp high density lipoprotein binding protein decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of HDLBP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HDLBP mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:93,948,099...94,018,040
Ensembl chr 9:93,949,913...94,018,048 		JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HERPUD1 mRNA CTD PMID:27188386 NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424 		JBrowse link
G Hes5 hes family bHLH transcription factor 5 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of HES5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001 		JBrowse link
G Hexa hexosaminidase subunit alpha increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of HEXA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEXA mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:59,936,526...59,961,654
Ensembl chr 8:59,936,660...59,962,013 		JBrowse link
G Hgsnat heparan-alpha-glucosaminide N-acetyltransferase decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of HGSNAT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HGSNAT mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:66,105,233...66,137,444
Ensembl chr16:66,105,181...66,136,138 		JBrowse link
G Hif3a hypoxia inducible factor 3 subunit alpha multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIF3A mRNA CTD PMID:27188386 NCBI chr 1:77,718,110...77,750,448
Ensembl chr 1:77,722,471...77,749,758 		JBrowse link
G Hist1h2al1 histone cluster 1 H2A family like 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of H2AC6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:42,707,954...42,708,420 JBrowse link
G Hist1h2bc histone cluster 1, H2bc decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of H2BC21 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC21 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:42,692,335...42,696,601
Ensembl chr17:42,694,723...42,696,642 		JBrowse link
G Hist1h2bd histone cluster 1 H2B family member D multiple interactions
decreases expression		 ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA
mercuric bromide results in decreased expression of H2BC5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:42,792,887...42,793,268 JBrowse link
G Hivep1 HIVEP zinc finger 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIVEP1 mRNA CTD PMID:27188386 NCBI chr17:22,585,016...22,714,517
Ensembl chr17:22,585,016...22,711,956 		JBrowse link
G Hmgcs1 3-hydroxy-3-methylglutaryl-CoA synthase 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of HMGCS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCS1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100 		JBrowse link
G Hmox1 heme oxygenase 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of HMOX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hnmt histamine N-methyltransferase increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of HNMT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:6,591,804...6,623,821
Ensembl chr 3:6,591,463...6,624,012 		JBrowse link
G Hnrnpr heterogeneous nuclear ribonucleoprotein R decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of HNRNPR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:148,542,999...148,574,888
Ensembl chr 5:148,543,044...148,574,867 		JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of HPGD mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228 		JBrowse link
G Hrh3 histamine receptor H3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of HRH3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRH3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:167,191,551...167,196,642
Ensembl chr 3:167,191,558...167,196,642 		JBrowse link
G Hrk harakiri, BCL2 interacting protein increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of HRK mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:38,387,484...38,409,652 JBrowse link
G Hs3st1 heparan sulfate-glucosamine 3-sulfotransferase 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of HS3ST1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HS3ST1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:71,185,826...71,223,263
Ensembl chr14:71,185,682...71,223,248 		JBrowse link
G Hs3st3a1 heparan sulfate-glucosamine 3-sulfotransferase 3A1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of HS3ST3A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3A1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:49,092,850...49,180,676
Ensembl chr10:49,094,026...49,180,676 		JBrowse link
G Hs3st3b1 heparan sulfate-glucosamine 3-sulfotransferase 3B1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of HS3ST3B1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:48,561,473...48,593,970
Ensembl chr10:48,561,473...48,593,970 		JBrowse link
G Hsd17b8 hydroxysteroid (17-beta) dehydrogenase 8 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of HSD17B8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSD17B8 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:4,826,725...4,828,742
Ensembl chr20:4,822,026...4,828,742 		JBrowse link
G Hspa4l heat shock protein family A (Hsp70) member 4 like increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of HSPA4L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:123,740,384...123,793,088
Ensembl chr 2:123,740,384...123,793,084 		JBrowse link
G Hspb8 heat shock protein family B (small) member 8 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPB8 mRNA CTD PMID:27188386 NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185 		JBrowse link
G Hsph1 heat shock protein family H (Hsp110) member 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPH1 mRNA CTD PMID:27188386 NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224 		JBrowse link
G Htatip2 HIV-1 Tat interactive protein 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of HTATIP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HTATIP2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629 		JBrowse link
G Htra1 HtrA serine peptidase 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of HTRA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HTRA1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379 		JBrowse link
G Id1 inhibitor of DNA binding 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ID1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419 		JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of IDH3A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084 		JBrowse link
G Ids iduronate 2-sulfatase increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of IDS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDS mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:149,025,976...149,046,641
Ensembl chr  X:149,025,976...149,046,663 		JBrowse link
G Ier3 immediate early response 3 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA CTD PMID:27188386 NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583 		JBrowse link
G Ifrd1 interferon-related developmental regulator 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFRD1 mRNA CTD PMID:27188386 NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990 		JBrowse link
G Ift57 intraflagellar transport 57 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of IFT57 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT57 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:51,051,520...51,124,909
Ensembl chr11:51,059,611...51,124,812 		JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of IGFBP3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083 		JBrowse link
G Igfbp5 insulin-like growth factor binding protein 5 decreases expression ISO mercuric bromide results in decreased expression of IGFBP5 mRNA CTD PMID:26272509 NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156 		JBrowse link
G Igfbp6 insulin-like growth factor binding protein 6 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP6 mRNA CTD PMID:27188386 NCBI chr 7:133,276,309...133,280,944
Ensembl chr 7:133,276,234...133,280,966 		JBrowse link
G Igfbp7 insulin-like growth factor binding protein 7 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of IGFBP7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314 		JBrowse link
G Igsf21 immunoglobin superfamily, member 21 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of IGSF21 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:152,287,834...152,512,174
Ensembl chr 5:152,287,835...152,512,174 		JBrowse link
G Il13ra1 interleukin 13 receptor subunit alpha 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of IL13RA1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL13RA1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:115,348,822...115,408,682
Ensembl chr  X:115,348,860...115,408,681
Ensembl chr11:115,348,860...115,408,681 		JBrowse link
G Il1rap interleukin 1 receptor accessory protein multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAP mRNA CTD PMID:27188386 NCBI chr11:74,062,999...74,199,530
Ensembl chr11:74,070,304...74,199,530 		JBrowse link
G Il6 interleukin 6 increases expression ISO mercuric bromide results in increased expression of IL6 mRNA CTD PMID:26272509 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Il6r interleukin 6 receptor increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of IL6R mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL6R mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536 		JBrowse link
G Inf2 inverted formin 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of INF2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:131,649,162...131,675,944
Ensembl chr 6:131,649,211...131,675,941 		JBrowse link
G Inhbe inhibin subunit beta E increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of INHBE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172 		JBrowse link
G Ino80d INO80 complex subunit D decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of INO80D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INO80D mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:64,447,075...64,514,013
Ensembl chr 9:64,457,165...64,515,242 		JBrowse link
G Inpp5d inositol polyphosphate-5-phosphatase D increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of INPP5D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746 		JBrowse link
G Insig1 insulin induced gene 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of INSIG1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INSIG1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952 		JBrowse link
G Iqce IQ motif containing E decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of IQCE mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IQCE mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:13,943,290...13,982,708
Ensembl chr12:13,943,487...13,982,693 		JBrowse link
G Irs1 insulin receptor substrate 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of IRS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRS1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122 		JBrowse link
G Isl1 ISL LIM homeobox 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA CTD PMID:27188386 NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584 		JBrowse link
G Isl2 ISL LIM homeobox 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL2 mRNA CTD PMID:27188386 NCBI chr 8:55,923,805...55,928,790
Ensembl chr 8:55,923,805...55,928,790 		JBrowse link
G Ist1 IST1 factor associated with ESCRT-III multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IST1 mRNA CTD PMID:27188386 NCBI chr19:37,648,840...37,671,019
Ensembl chr19:37,648,095...37,670,956 		JBrowse link
G Itga4 integrin subunit alpha 4 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of ITGA4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGA4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:64,162,764...64,235,010
Ensembl chr 3:64,163,085...64,233,715 		JBrowse link
G Itga8 integrin subunit alpha 8 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ITGA8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:75,304,004...75,501,510
Ensembl chr17:75,304,008...75,501,510 		JBrowse link
G Itgb6 integrin subunit beta 6 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ITGB6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGB6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671 		JBrowse link
G Itih5 inter-alpha-trypsin inhibitor heavy chain 5 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ITIH5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:68,248,115...68,352,216
Ensembl chr17:68,252,128...68,352,207 		JBrowse link
G Itm2a integral membrane protein 2A increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ITM2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:72,486,383...72,492,344
Ensembl chr  X:72,486,381...72,492,363 		JBrowse link
G Itm2b integral membrane protein 2B increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ITM2B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2B mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:48,545,998...48,568,904
Ensembl chr15:48,546,001...48,568,917 		JBrowse link
G Itpr2 inositol 1,4,5-trisphosphate receptor, type 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ITPR2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:179,028,594...179,434,657
Ensembl chr 4:179,027,281...179,404,164 		JBrowse link
G Jam2 junctional adhesion molecule 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of JAM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAM2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:23,830,820...23,880,071
Ensembl chr11:23,831,106...23,880,063 		JBrowse link
G Jazf1 JAZF zinc finger 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of JAZF1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAZF1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:81,879,501...82,183,237
Ensembl chr 4:81,881,061...82,183,100 		JBrowse link
G Jph4 junctophilin 4 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of JPH4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JPH4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:28,579,579...28,588,903
Ensembl chr15:28,571,568...28,587,573 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JUN mRNA CTD PMID:27188386 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Kat6a lysine acetyltransferase 6A decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of KAT6A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:69,084,914...69,165,923
Ensembl chr16:69,084,914...69,163,606 		JBrowse link
G Katnbl1 katanin regulatory subunit B1 like 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of KATNBL1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KATNBL1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:99,183,748...99,225,789
Ensembl chr 3:99,183,716...99,225,786 		JBrowse link
G Kcnj12 potassium inwardly-rectifying channel, subfamily J, member 12 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of KCNJ12 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ12 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:45,696,621...45,745,528
Ensembl chr10:45,696,849...45,745,492 		JBrowse link
G Kcnk1 potassium two pore domain channel subfamily K member 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of KCNK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:53,959,411...53,997,726
Ensembl chr19:53,959,657...53,997,724 		JBrowse link
G Kcnk10 potassium two pore domain channel subfamily K member 10 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of KCNK10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:117,690,052...117,826,120
Ensembl chr 6:117,694,222...117,825,695 		JBrowse link
G Kcnq2 potassium voltage-gated channel subfamily Q member 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of KCNQ2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNQ2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:168,194,776...168,253,831
Ensembl chr 3:168,195,357...168,275,071 		JBrowse link
G Kctd1 potassium channel tetramerization domain containing 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of KCTD1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:6,122,390...6,316,434
Ensembl chr18:6,122,390...6,317,393 		JBrowse link
G Kctd12 potassium channel tetramerization domain containing 12 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of KCTD12 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:79,800,078...79,806,017
Ensembl chr15:79,801,191...79,806,282 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of KEAP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KEAP1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862 		JBrowse link
G Kif1a kinesin family member 1A multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIF1A mRNA CTD PMID:27188386 NCBI chr 9:93,563,033...93,647,412
Ensembl chr 9:93,563,045...93,647,480 		JBrowse link
G Kitlg KIT ligand increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of KITLG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214 		JBrowse link
G Klf11 KLF transcription factor 11 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of KLF11 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLF11 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:41,285,699...41,297,548
Ensembl chr 6:41,285,842...41,297,550 		JBrowse link
G Klf5 KLF transcription factor 5 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of KLF5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445 		JBrowse link
G Klf6 KLF transcription factor 6 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of KLF6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570 		JBrowse link
G Klf9 KLF transcription factor 9 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA CTD PMID:27188386 NCBI chr 1:220,700,108...220,725,110
Ensembl chr 1:220,700,108...220,725,037 		JBrowse link
G Klhdc8a kelch domain containing 8A decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of KLHDC8A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHDC8A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:43,735,702...43,744,277
Ensembl chr13:43,736,192...43,744,277 		JBrowse link
G Klhl21 kelch-like family member 21 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL21 mRNA CTD PMID:27188386 NCBI chr 5:162,514,888...162,523,545
Ensembl chr 5:162,514,765...162,523,545 		JBrowse link
G Klhl4 kelch-like family member 4 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL4 mRNA CTD PMID:27188386 NCBI chr  X:79,429,193...79,719,482
Ensembl chr  X:79,622,113...79,719,480 		JBrowse link
G Klhl5 kelch-like family member 5 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLHL5 mRNA CTD PMID:27188386 NCBI chr14:43,144,254...43,206,192
Ensembl chr14:43,144,257...43,184,238 		JBrowse link
G Klk8 kallikrein related-peptidase 8 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of KLK8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KLK8 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:94,251,803...94,258,646
Ensembl chr 1:94,251,803...94,258,646 		JBrowse link
G Kndc1 kinase non-catalytic C-lobe domain containing 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of KNDC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KNDC1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:194,689,962...194,738,353
Ensembl chr 1:194,690,135...194,738,362 		JBrowse link
G Kras KRAS proto-oncogene, GTPase decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of KRAS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KRAS mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:178,185,418...178,218,484 JBrowse link
G Krt18 keratin 18 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of KRT18 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
Ensembl chr10:133,157,475...133,161,166 		JBrowse link
G Krt8 keratin 8 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of KRT8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728 		JBrowse link
G Lacc1 laccase domain containing 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of LACC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:52,390,267...52,407,630
Ensembl chr15:52,395,183...52,407,545 		JBrowse link
G Lactb lactamase, beta multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA CTD PMID:27188386 NCBI chr 8:67,571,504...67,587,592
Ensembl chr 8:67,571,500...67,587,539 		JBrowse link
G Lamc2 laminin subunit gamma 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of LAMC2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200 		JBrowse link
G Lamp2 lysosomal-associated membrane protein 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of LAMP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:117,173,097...117,222,090
Ensembl chr  X:117,057,606...117,260,522 		JBrowse link
G Layn layilin increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of LAYN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:51,363,928...51,384,748
Ensembl chr 8:51,367,091...51,384,330 		JBrowse link
G Lgals3 galectin 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of LGALS3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025 		JBrowse link
G Lgals8 galectin 8 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of LGALS8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS8 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:58,024,652...58,052,764
Ensembl chr17:58,028,105...58,052,764 		JBrowse link
G Lhfpl4 LHFPL tetraspan subfamily member 4 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of LHFPL4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHFPL4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:146,317,110...146,340,073
Ensembl chr 4:146,313,541...146,340,463 		JBrowse link
G Lhfpl6 LHFPL tetraspan subfamily member 6 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of LHFPL6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:137,126,485...137,324,442
Ensembl chr 2:137,126,509...137,324,443 		JBrowse link
G Lhx2 LIM homeobox 2 decreases expression ISO mercuric bromide results in decreased expression of LHX2 mRNA CTD PMID:26272509 NCBI chr 3:22,113,619...22,143,909
Ensembl chr 3:22,126,007...22,143,908 		JBrowse link
G Lhx4 LIM homeobox 4 increases expression ISO mercuric bromide results in increased expression of LHX4 mRNA CTD PMID:26272509 NCBI chr13:67,877,109...67,917,219
Ensembl chr13:67,877,109...67,927,003 		JBrowse link
G Lhx8 LIM homeobox 8 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA CTD PMID:27188386 NCBI chr 2:243,244,958...243,269,624
Ensembl chr 2:243,244,961...243,269,416 		JBrowse link
G Lifr LIF receptor subunit alpha increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of LIFR mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:56,250,120...56,286,699 		JBrowse link
G Lim2 lens intrinsic membrane protein 2 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA CTD PMID:27188386 NCBI chr 1:93,837,597...93,843,769
Ensembl chr 1:93,837,597...93,843,769 		JBrowse link
G Limch1 LIM and calponin homology domains 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIMCH1 mRNA CTD PMID:27188386 NCBI chr14:41,112,579...41,425,001
Ensembl chr14:41,114,803...41,425,191 		JBrowse link
G Lix1 limb and CNS expressed 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of LIX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:58,128,961...58,187,554
Ensembl chr 1:58,128,961...58,185,964 		JBrowse link
G Lman1 lectin, mannose-binding, 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of LMAN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:59,508,996...59,530,873
Ensembl chr18:59,508,996...59,530,851 		JBrowse link
G Lmna lamin A/C increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of LMNA mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMNA mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423 		JBrowse link
G Lmo1 LIM domain only 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of LMO1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:163,132,338...163,168,521
Ensembl chr 1:163,132,339...163,168,522 		JBrowse link
G Lmo3 LIM domain only 3 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of LMO3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:171,234,686...171,297,677
Ensembl chr 4:171,234,696...171,292,222 		JBrowse link
G Lmo7 LIM domain 7 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of LMO7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:78,566,999...78,769,833
Ensembl chr15:78,567,023...78,769,783 		JBrowse link
G Lnx1 ligand of numb-protein X 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of LNX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:33,514,429...33,617,086
Ensembl chr14:33,514,436...33,617,086 		JBrowse link
G Lpar3 lysophosphatidic acid receptor 3 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of LPAR3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LPAR3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:235,125,234...235,193,916
Ensembl chr 2:235,149,065...235,193,357 		JBrowse link
G Lpar6 lysophosphatidic acid receptor 6 increases expression ISO mercuric bromide results in increased expression of LPAR6 mRNA CTD PMID:26272509 NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331 		JBrowse link
G Lrp10 LDL receptor related protein 10 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of LRP10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRP10 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:27,921,335...27,927,507
Ensembl chr15:27,920,259...27,927,505 		JBrowse link
G Lrrc34 leucine rich repeat containing 34 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of LRRC34 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC34 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:112,752,294...112,774,463
Ensembl chr 2:112,754,578...112,774,459 		JBrowse link
G Lrrc3b leucine rich repeat containing 3B decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of LRRC3B mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:9,973,580...10,050,891
Ensembl chr15:9,969,983...10,051,066 		JBrowse link
G Lrrn4 leucine rich repeat neuronal 4 increases expression ISO mercuric bromide results in increased expression of LRRN4 mRNA CTD PMID:26272509 NCBI chr 3:120,138,093...120,150,877
Ensembl chr 3:120,139,410...120,150,831 		JBrowse link
G Lsamp limbic system-associated membrane protein decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of LSAMP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSAMP mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:58,547,533...60,717,328
Ensembl chr11:58,554,805...60,717,029 		JBrowse link
G Ly6k lymphocyte antigen 6 family member K increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of LY6K mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY6K mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:106,683,749...106,712,802
Ensembl chr 7:106,683,753...106,686,372 		JBrowse link
G Lyve1 lymphatic vessel endothelial hyaluronan receptor 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of LYVE1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYVE1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:164,962,872...164,976,309
Ensembl chr 1:164,962,872...164,976,309 		JBrowse link
G Lzts1 leucine zipper tumor suppressor 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA CTD PMID:27188386 NCBI chr16:20,542,756...20,598,204
Ensembl chr16:20,542,809...20,598,203 		JBrowse link
G Mab21l2 mab-21 like 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MAB21L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:171,946,573...171,949,655
Ensembl chr 2:171,946,573...171,949,655 		JBrowse link
G Macc1 MET transcriptional regulator MACC1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MACC1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:140,352,690...140,430,255
Ensembl chr 6:140,352,755...140,430,255 		JBrowse link
G Macroh2a1 macroH2A.1 histone decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MACROH2A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:8,479,331...8,542,071
Ensembl chr17:8,479,372...8,542,072 		JBrowse link
G Mafb MAF bZIP transcription factor B multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFB mRNA CTD PMID:27188386 NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031 		JBrowse link
G Maff MAF bZIP transcription factor F multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFF mRNA CTD PMID:27188386 NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851 		JBrowse link
G Mafg MAF bZIP transcription factor G increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MAFG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAFG mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026 		JBrowse link
G Mal2 mal, T-cell differentiation protein 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MAL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAL2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:85,900,453...85,933,433
Ensembl chr 7:85,900,453...85,933,429 		JBrowse link
G Man1a1 mannosidase, alpha, class 1A, member 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MAN1A1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAN1A1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:33,202,509...33,385,747
Ensembl chr20:33,202,517...33,385,824 		JBrowse link
G Man1c1 mannosidase, alpha, class 1C, member 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MAN1C1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAN1C1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:146,774,282...146,913,257
Ensembl chr 5:146,775,842...146,913,421 		JBrowse link
G Map1a microtubule-associated protein 1A increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MAP1A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:108,263,217...108,283,936
Ensembl chr 3:108,263,151...108,282,899 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MAP2K6 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293 		JBrowse link
G Map3k14 mitogen-activated protein kinase kinase kinase 14 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K14 mRNA CTD PMID:27188386 NCBI chr10:88,165,349...88,215,558
Ensembl chr10:88,165,351...88,215,523 		JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K5 mRNA CTD PMID:27188386 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800 		JBrowse link
G Map4 microtubule-associated protein 4 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MAP4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:109,925,233...110,064,370
Ensembl chr 8:109,925,575...110,064,362 		JBrowse link
G Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 increases expression ISO mercuric bromide results in increased expression of MAP4K4 mRNA CTD PMID:26272509 NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698 		JBrowse link
G Map6 microtubule-associated protein 6 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA CTD PMID:27188386 NCBI chr 1:153,568,020...153,634,415
Ensembl chr 1:153,568,368...153,634,414 		JBrowse link
G Map7 microtubule-associated protein 7 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MAP7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:14,910,433...15,037,574
Ensembl chr 1:14,910,551...15,037,574 		JBrowse link
G Mapk10 mitogen activated protein kinase 10 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MAPK10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAPK10 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201 		JBrowse link
G Marveld3 MARVEL domain containing 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MARVELD3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MARVELD3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:37,908,727...37,923,420
Ensembl chr19:37,905,638...37,923,420 		JBrowse link
G Mast4 microtubule associated serine/threonine kinase family member 4 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MAST4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAST4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:33,893,241...34,483,682
Ensembl chr 2:33,894,436...34,483,723 		JBrowse link
G Mbd2 methyl-CpG binding domain protein 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MBD2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBD2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:64,174,002...64,240,795
Ensembl chr18:64,174,002...64,240,794 		JBrowse link
G Mbnl3 muscleblind-like splicing regulator 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MBNL3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:130,641,942...130,737,179
Ensembl chr  X:130,648,538...130,737,056 		JBrowse link
G Mboat1 membrane bound O-acyltransferase domain containing 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MBOAT1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBOAT1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:34,331,413...34,445,088
Ensembl chr17:34,331,422...34,445,088 		JBrowse link
G Mcc MCC regulator of WNT signaling pathway increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MCC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCC mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:36,794,206...37,266,237
Ensembl chr18:36,798,372...37,266,819 		JBrowse link
G Mcm7 minichromosome maintenance complex component 7 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MCM7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCM7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063 		JBrowse link
G Mcoln3 mucolipin TRP cation channel 3 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MCOLN3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:235,008,716...235,042,885
Ensembl chr 2:234,966,010...235,043,047 		JBrowse link
G Mctp1 multiple C2 and transmembrane domain containing 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MCTP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCTP1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:6,071,408...6,761,833
Ensembl chr 2:6,065,808...6,761,833 		JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MDM2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915 		JBrowse link
G Me1 malic enzyme 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of ME1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ME1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304 		JBrowse link
G Megf10 multiple EGF-like domains 10 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MEGF10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEGF10 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr18:50,605,231...50,755,441
Ensembl chr18:50,605,656...50,754,456 		JBrowse link
G Meiob meiosis specific with OB-fold decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MEIOB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MEIOB mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:13,833,170...13,865,684
Ensembl chr10:13,833,750...13,865,046 		JBrowse link
G Meltf melanotransferrin decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MELTF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MELTF mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:68,884,446...68,906,300
Ensembl chr11:68,884,446...68,906,300 		JBrowse link
G Meox1 mesenchyme homeobox 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MEOX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:86,818,450...86,837,563
Ensembl chr10:86,818,478...86,837,660 		JBrowse link
G Mfap3l microfibril associated protein 3 like decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MFAP3L mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFAP3L mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:29,411,643...29,454,665
Ensembl chr16:29,415,849...29,430,863 		JBrowse link
G Mfap5 microfibril associated protein 5 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MFAP5 mRNA CTD PMID:27188386 NCBI chr 4:155,727,925...155,750,458
Ensembl chr 4:155,727,925...155,750,458 		JBrowse link
G Mfng MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MFNG mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:110,310,810...110,328,653
Ensembl chr 7:110,310,812...110,328,653 		JBrowse link
G Mgarp mitochondria-localized glutamic acid-rich protein multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MGARP mRNA CTD PMID:27188386 NCBI chr 2:135,431,283...135,439,425
Ensembl chr 2:135,431,283...135,439,612 		JBrowse link
G Mif4gd MIF4G domain containing decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MIF4GD mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIF4GD mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:100,847,168...100,852,166 JBrowse link
G Mitf melanocyte inducing transcription factor increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MITF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MITF mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145 		JBrowse link
G Mmab metabolism of cobalamin associated B decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MMAB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MMAB mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:42,159,109...42,172,518
Ensembl chr12:42,159,089...42,172,490 		JBrowse link
G Mmp14 matrix metallopeptidase 14 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MMP14 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MMP14 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864 		JBrowse link
G Mmp16 matrix metallopeptidase 16 decreases expression ISO mercuric bromide results in decreased expression of MMP16 mRNA CTD PMID:26272509 NCBI chr 5:31,312,280...31,556,276
Ensembl chr 5:31,312,280...31,548,388 		JBrowse link
G Mnx1 motor neuron and pancreas homeobox 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MNX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MNX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 4:5,866,506...5,871,465
Ensembl chr 4:5,866,506...5,871,465 		JBrowse link
G Mpzl2 myelin protein zero-like 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MPZL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MPZL2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:45,348,285...45,359,298
Ensembl chr 8:45,348,285...45,359,298 		JBrowse link
G Mrgprf MAS related GPR family member F multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MRGPRF mRNA CTD PMID:27188386 NCBI chr 1:200,464,100...200,473,588
Ensembl chr 1:200,463,973...200,473,660 		JBrowse link
G Mrpl4 mitochondrial ribosomal protein L4 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MRPL4 mRNA CTD PMID:27188386 NCBI chr 8:19,539,593...19,545,608
Ensembl chr 8:19,539,593...19,545,608 		JBrowse link
G Msrb3 methionine sulfoxide reductase B3 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MSRB3 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MSRB3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:56,260,985...56,426,004
Ensembl chr 7:56,303,308...56,425,496 		JBrowse link
G Msx1 msh homeobox 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MSX1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:72,961,036...72,964,970
Ensembl chr14:72,961,148...72,964,966 		JBrowse link
G Msx2 msh homeobox 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MSX2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:11,097,214...11,102,879
Ensembl chr17:11,097,103...11,102,879 		JBrowse link
G Mt1-ps3 metallothionein 1, pseudogene 3 multiple interactions
increases expression		 ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1E mRNA
mercuric bromide results in increased expression of MT1E mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:74,786,652...74,787,040
Ensembl chr17:74,786,654...74,787,135 		JBrowse link
G Mt2-ps1 metallothionein 2, pseudogene 1 multiple interactions
increases expression		 ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT1HL1 mRNA
mercuric bromide results in increased expression of MT1HL1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr20:3,159,037...3,159,409
Ensembl chr 5:119,728,811...119,730,073 		JBrowse link
G Mt2A metallothionein 2A increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MT2A mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MT2A mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784 		JBrowse link
G Mtss1 MTSS I-BAR domain containing 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MTSS1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MTSS1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:90,488,751...90,628,007
Ensembl chr 7:90,488,754...90,627,968 		JBrowse link
G Muc15 mucin 15, cell surface associated increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MUC15 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:97,294,728...97,308,641
Ensembl chr 3:97,294,783...97,307,090 		JBrowse link
G Mycl MYCL proto-oncogene, bHLH transcription factor decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MYCL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYCL mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:135,274,713...135,281,584
Ensembl chr 5:135,274,748...135,281,582 		JBrowse link
G Myct1 myc target 1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYCT1 mRNA CTD PMID:27188386 NCBI chr 1:42,018,137...42,029,410
Ensembl chr 1:42,018,137...42,029,410 		JBrowse link
G Mylk myosin light chain kinase decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of MYLK mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261 		JBrowse link
G Myo10 myosin X increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MYO10 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO10 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:76,100,989...76,305,619
Ensembl chr 2:76,100,987...76,303,030 		JBrowse link
G Myo1d myosin ID increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MYO1D mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO1D mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:65,489,153...65,765,812
Ensembl chr10:65,489,154...65,766,349 		JBrowse link
G Myof myoferlin increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of MYOF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYOF mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334 		JBrowse link
G N4bp2l2 NEDD4 binding protein 2-like 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of N4BP2L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of N4BP2L2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr12:137,342...200,292
Ensembl chr12:103,590...197,784 		JBrowse link
G Nabp1 nucleic acid binding protein 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of NABP1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NABP1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 9:50,098,552...50,133,982
Ensembl chr 9:50,126,726...50,134,107 		JBrowse link
G Nat1 N-acetyltransferase 1 increases expression ISO mercuric bromide results in increased expression of NAT1 mRNA CTD PMID:26272509 NCBI chr16:22,218,217...22,238,516
Ensembl chr16:22,208,194...22,238,520 		JBrowse link
G Nav1 neuron navigator 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of NAV1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NAV1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:46,866,972...47,119,368
Ensembl chr13:46,873,689...47,126,449 		JBrowse link
G Ncald neurocalcin delta decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of NCALD mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:68,532,671...68,964,740
Ensembl chr 7:68,534,421...68,964,496 		JBrowse link
G Ncam1 neural cell adhesion molecule 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of NCAM1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAM1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014 		JBrowse link
G Ncan neurocan decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of NCAN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCAN mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr16:19,301,969...19,328,436
Ensembl chr16:19,301,969...19,328,436 		JBrowse link
G Ncoa7 nuclear receptor coactivator 7 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of NCOA7 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCOA7 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:26,856,228...27,016,950
Ensembl chr 1:26,856,530...27,015,871 		JBrowse link
G Ndfip2 Nedd4 family interacting protein 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of NDFIP2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NDFIP2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:82,032,366...82,087,043
Ensembl chr15:82,032,366...82,086,317 		JBrowse link
G Ndp norrin cystine knot growth factor NDP decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of NDP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:5,796,487...5,820,934
Ensembl chr  X:5,796,487...5,820,934 		JBrowse link
G Ndst4 N-deacetylase and N-sulfotransferase 4 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NDST4 mRNA CTD PMID:27188386 NCBI chr 2:213,787,010...214,119,514
Ensembl chr 2:213,787,006...214,115,373 		JBrowse link
G Ndufb1 NADH:ubiquinone oxidoreductase subunit B1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of NDUFB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDUFB1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 6:121,115,649...121,124,055 JBrowse link
G Nectin4 nectin cell adhesion molecule 4 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of NECTIN4 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NECTIN4 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:83,802,589...83,821,711
Ensembl chr13:83,803,184...83,821,709 		JBrowse link
G Nefh neurofilament heavy chain decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of NEFH mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEFH mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351 		JBrowse link
G Nefl neurofilament light chain increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of NEFL mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFL mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793 		JBrowse link
G Nefm neurofilament medium chain increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of NEFM mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEFM mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755 		JBrowse link
G Neil2 nei-like DNA glycosylase 2 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of NEIL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEIL2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr15:37,444,676...37,454,863
Ensembl chr15:37,445,381...37,454,863 		JBrowse link
G Nexmif neurite extension and migration factor decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of NEXMIF mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:69,088,076...69,219,253
Ensembl chr  X:69,088,076...69,112,930 		JBrowse link
G Nf1 neurofibromin 1 decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of NF1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NF1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658 		JBrowse link
G Nfasc neurofascin decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of NFASC mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFASC mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:43,997,223...44,183,863
Ensembl chr13:43,997,224...44,183,880 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of NFE2L2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFE2L2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfib nuclear factor I/B increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of NFIB mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NFIB mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:96,759,208...96,974,001
Ensembl chr 5:96,764,653...96,975,479 		JBrowse link
G Nhlh2 nescient helix loop helix 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of NHLH2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NHLH2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:189,444,287...189,449,625
Ensembl chr 2:189,442,711...189,449,625 		JBrowse link
G Nhs NHS actin remodeling regulator decreases expression
multiple interactions		 ISO mercuric bromide results in decreased expression of NHS mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NHS mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr  X:32,553,300...32,892,961
Ensembl chr  X:32,552,026...32,889,992 		JBrowse link
G Niban1 niban apoptosis regulator 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of NIBAN1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIBAN1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr13:63,674,240...63,827,748
Ensembl chr13:63,674,171...63,827,729 		JBrowse link
G Nipal2 NIPA-like domain containing 2 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of NIPAL2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NIPAL2 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 7:65,774,477...65,884,807
Ensembl chr 7:65,774,477...65,884,807 		JBrowse link
G Nkain3 Sodium/potassium transporting ATPase interacting 3 multiple interactions
decreases expression		 ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA
mercuric bromide results in decreased expression of NKAIN3 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 5:33,613,720...34,310,090
Ensembl chr 5:33,623,713...34,309,381 		JBrowse link
G Nln neurolysin increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of NLN mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NLN mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:35,133,634...35,232,927
Ensembl chr 2:35,134,145...35,232,914 		JBrowse link
G Nlrx1 NLR family member X1 multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLRX1 mRNA CTD PMID:27188386 NCBI chr 8:44,588,476...44,606,678
Ensembl chr 8:44,590,048...44,606,484 		JBrowse link
G Nme8 NME/NM23 family member 8 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of NME8 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr17:45,237,022...45,304,948
Ensembl chr17:45,238,120...45,304,948 		JBrowse link
G Nmrk1 nicotinamide riboside kinase 1 increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of NMRK1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMRK1 mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 1:216,049,350...216,076,792
Ensembl chr 1:216,049,437...216,076,791 		JBrowse link
G Noct nocturnin increases expression
multiple interactions		 ISO mercuric bromide results in increased expression of NOCT mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA		 CTD PMID:26272509 PMID:27188386 NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400 		JBrowse link
G Nog noggin multiple interactions ISO [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] affects the expression of ARAP2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of A1BG mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCC4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACTN3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADCYAP1R1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFAP1L2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AFDN-DT mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APBA2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of APCDD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF25 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARRDC2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASPHD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATL3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP2B1-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP8A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B9D1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCO1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEND4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BOC mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BST2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C11ORF96 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF226 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF70 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACHD1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAMK2N1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCBE1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC102A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CD40 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP263 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP300 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP96 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHRDL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CIMAP1B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLEC18A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNFN mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTNAP3P2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COPS8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTDSP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUTALP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CXCR4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCX mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DHRS11 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DICER1-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DOCK7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DRD4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DSTYK mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EEF1AKMT2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFHC2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGFL7 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EID3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERICH1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERO1B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EVC2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXD3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FKBP5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRMD3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAL mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT10 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GALNT14 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAS2L1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GCNT1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GDAP1L1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNAS-AS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNE mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPM6B mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR153 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRAMD1C mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSTM2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GUCA1A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC21 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HCG11 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HDLBP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HGSNAT mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIF3A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HIVEP1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMB mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DOA mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCS1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3A1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSD17B8 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HTRA1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT57 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP3 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAP mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INO80D mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of INSIG1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPW mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IQCE mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IST1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGA4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAM2 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JAZF1 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of JPH4 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ12 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA; [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decre